{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T11:10:06Z","timestamp":1735729806240,"version":"3.32.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"DOI":"10.7759\/cureus.76720","type":"journal-article","created":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T10:28:36Z","timestamp":1735727316000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Immunologic Manifestations of Antiphospholipid Syndrome Among Patients in King Abdulaziz Medical City (KAMC), Jeddah, Saudi Arabia"],"prefix":"10.7759","author":[{"given":"Rami F","family":"Magliah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda H","family":"Ashkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fayez S","family":"Alharthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit JY","year":"2022","unstructured":"Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-Garc\u00eda A. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep. 2022, 23:85. 10.1007\/s11926-021-01038-2","journal-title":"Curr Rheumatol Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00941","article-title":"Cardiac manifestations of antiphospholipid syndrome with focus on its primary form","volume":"10","author":"Kolitz T","year":"2019","unstructured":"Kolitz T, Shiber S, Sharabi I, Winder A, Zandman-Goddard G. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol. 2019, 10:941. 10.3389\/fimmu.2019.00941","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/antib13010021","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"13","author":"Jacobs L","year":"2024","unstructured":"Jacobs L, Wauters N, Lablad Y, Morelle J, Taghavi M. Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Antibodies (Basel). 2024, 13:21. 10.3390\/antib13010021","journal-title":"Antibodies (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/bacteria3040022","article-title":"Complex interaction between gut microbiome and autoimmunity: focus on antiphospholipid syndrome","volume":"3","author":"Akinsulie OC","year":"2024","unstructured":"Akinsulie OC, Olowu BI, Adesola RO, et al.. Complex interaction between gut microbiome and autoimmunity: focus on antiphospholipid syndrome. Bacteria. 2024, 3:330-43. 10.3390\/bacteria3040022","journal-title":"Bacteria"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320950461","article-title":"16th International Congress on Antiphospholipid Antibodies task force report on antiphospholipid syndrome treatment trends","volume":"29","author":"Cohen H","year":"2020","unstructured":"Cohen H, Cuadrado MJ, Erkan D, et al.. 16th International Congress on Antiphospholipid Antibodies task force report on antiphospholipid syndrome treatment trends. Lupus. 2020, 29:1571-93. 10.1177\/0961203320950461","journal-title":"Lupus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1556725","article-title":"Antiphospholipid syndrome--not a noninflammatory disease","volume":"41","author":"de Groot PG","year":"2015","unstructured":"de Groot PG, Urbanus RT. Antiphospholipid syndrome--not a noninflammatory disease. Semin Thromb Hemost. 2015, 41:607-14. 10.1055\/s-0035-1556725","journal-title":"Semin Thromb Hemost"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35551","article-title":"Map of autosomal recessive genetic disorders in Saudi Arabia: concepts and future directions","volume":"158A","author":"Al-Owain M","year":"2012","unstructured":"Al-Owain M, Al-Zaidan H, Al-Hassnan Z. Map of autosomal recessive genetic disorders in Saudi Arabia: concepts and future directions. Am J Med Genet A. 2012, 158A:2629-40. 10.1002\/ajmg.a.35551","journal-title":"Am J Med Genet A"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2020.05.037","article-title":"The clinical and laboratory manifestations profile of antiphospholipid syndrome among Saudi Arabia population: examining the applicability of Sapporo criteria","volume":"27","author":"Algahtani FH","year":"2020","unstructured":"Algahtani FH, AlQahtany FS, ElGohary G, Alsharidi A, Sayeeda A, AlArfaj H, Gamal AY. The clinical and laboratory manifestations profile of antiphospholipid syndrome among Saudi Arabia population: examining the applicability of Sapporo criteria. Saudi J Biol Sci. 2020, 27:2425-30. 10.1016\/j.sjbs.2020.05.037","journal-title":"Saudi J Biol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23584","article-title":"The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Clinical Database and Repository","volume":"71","author":"Unlu O","year":"2019","unstructured":"Unlu O, Erkan D, Barbhaiya M, et al.. The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Clinical Database and Repository. Arthritis Care Res (Hoboken). 2019, 71:134-41. 10.1002\/acr.23584","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: a population-based study","volume":"71","author":"Duarte-Garc\u00eda A","year":"2019","unstructured":"Duarte-Garc\u00eda A, Pham MM, Crowson CS, et al.. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheumatol. 2019, 71:1545-52. 10.1002\/art.40901","journal-title":"Arthritis Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.33590\/emjrheumatol\/10314116","article-title":"Update on the diagnosis and anticoagulant treatment of the antiphospholipid syndrome","volume":"6","author":"Riva N","year":"2019","unstructured":"Riva N, Gatt A. Update on the diagnosis and anticoagulant treatment of the antiphospholipid syndrome. EMJ Rheumatol. 2019, 6:101-11. 10.33590\/emjrheumatol\/10314116","journal-title":"EMJ Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(17)30066-X","article-title":"Antiphospholipid syndrome","volume":"151","author":"Cervera R","year":"2017","unstructured":"Cervera R. Antiphospholipid syndrome. Thromb Res. 2017, 151:43-7. 10.1016\/S0049-3848(17)30066-X","journal-title":"Thromb Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27313","article-title":"Suspected COVID-19 immunization-induced probable catastrophic antiphospholipid syndrome","volume":"14","author":"Seeley EA","year":"2022","unstructured":"Seeley EA, Zimmer M, Berghea R. Suspected COVID-19 immunization-induced probable catastrophic antiphospholipid syndrome. Cureus. 2022, 14:e27313. 10.7759\/cureus.27313","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou MG","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M, et al.. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019, 78:1296-304. 10.1136\/annrheumdis-2019-215213","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144191","article-title":"Antiphospholipid syndrome: insights into molecular mechanisms and clinical manifestations","volume":"13","author":"Celia AI","year":"2024","unstructured":"Celia AI, Galli M, Mancuso S, Alessandri C, Frati G, Sciarretta S, Conti F. Antiphospholipid syndrome: insights into molecular mechanisms and clinical manifestations. J Clin Med. 2024, 13:4191. 10.3390\/jcm13144191","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002881","article-title":"Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study","volume":"9","author":"Guedon AF","year":"2023","unstructured":"Guedon AF, Ricard L, Laurent C, et al.. Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study. RMD Open. 2023, 9:10.1136\/rmdopen-2022-002881","journal-title":"RMD Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-022-00409-8","article-title":"The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study","volume":"20","author":"Yao WC","year":"2022","unstructured":"Yao WC, Leong KH, Chiu LT, et al.. The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study. Thromb J. 2022, 20:50. 10.1186\/s12959-022-00409-8","journal-title":"Thromb J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02155-y","article-title":"Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome","volume":"50","author":"Arantes FT","year":"2020","unstructured":"Arantes FT, Mazetto BM, Saraiva SS, Tobaldini LQ, Dos Santos AP, Annichino-Bizzacchi J, Orsi FA. Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome. J Thromb Thrombolysis. 2020, 50:772-81. 10.1007\/s11239-020-02155-y","journal-title":"J Thromb Thrombolysis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14720","article-title":"Prevalence of confirmed antiphospholipid syndrome in 18-50 years unselected patients with first unprovoked venous thromboembolism","volume":"18","author":"Miranda S","year":"2020","unstructured":"Miranda S, Park J, Le Gal G, Piran S, Kherani S, Rodger MA, Delluc A. Prevalence of confirmed antiphospholipid syndrome in 18-50 years unselected patients with first unprovoked venous thromboembolism. J Thromb Haemost. 2020, 18:926-30. 10.1111\/jth.14720","journal-title":"J Thromb Haemost"},{"key":"ref20","article-title":"Correlation between antiphospholipid antibodies and recurrent spontaneous miscarriage in Saudi women","volume":"8","author":"Ali ST","year":"2019","unstructured":"Ali ST, Omar OS. Correlation between antiphospholipid antibodies and recurrent spontaneous miscarriage in Saudi women. Int J Sci Res. 2019, 8:.1106-111.","journal-title":"Int J Sci Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2021.1969116","article-title":"Obstetric anti-phospholipid syndrome: from pathogenesis to treatment","volume":"45","author":"Kaneko K","year":"2022","unstructured":"Kaneko K, Ozawa N, Murashima A. Obstetric anti-phospholipid syndrome: from pathogenesis to treatment. Immunol Med. 2022, 45:79-93. 10.1080\/25785826.2021.1969116","journal-title":"Immunol Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043195","article-title":"Antiphospholipid syndrome in pregnancy: new and old pathogenetic mechanisms","volume":"24","author":"D'Ippolito S","year":"2023","unstructured":"D'Ippolito S, Barbaro G, Paciullo C, Tersigni C, Scambia G, Di Simone N. Antiphospholipid syndrome in pregnancy: new and old pathogenetic mechanisms. Int J Mol Sci. 2023, 24:3195. 10.3390\/ijms24043195","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia D","year":"2018","unstructured":"Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018, 378:2010-21. 10.1056\/NEJMra1705454","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14010024","article-title":"Stroke and risk factors in antiphospholipid syndrome","volume":"14","author":"Fan Y","year":"2023","unstructured":"Fan Y, Xu Y, Zhang S, Song X, Liu Z, Tu W, Li C. Stroke and risk factors in antiphospholipid syndrome. J Pers Med. 2023, 14:24. 10.3390\/jpm14010024","journal-title":"J Pers Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4431907","article-title":"Was antiphospholipid syndrome a risk factor of stroke? A systemic review and meta-analysis of cohort studies","volume":"2021","author":"Zhao K","year":"2021","unstructured":"Zhao K, Zhou P, Xu L, et al.. Was antiphospholipid syndrome a risk factor of stroke? A systemic review and meta-analysis of cohort studies. Dis Markers. 2021, 2021:4431907. 10.1155\/2021\/4431907","journal-title":"Dis Markers"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/17474930221150349","article-title":"Antiphospholipid syndrome, antiphospholipid antibodies, and stroke","volume":"18","author":"Mittal P","year":"2023","unstructured":"Mittal P, Quattrocchi G, Tohidi-Esfahani I, Sayar Z, Chandratheva A, Cohen H. Antiphospholipid syndrome, antiphospholipid antibodies, and stroke. Int J Stroke. 2023, 18:383-91. 10.1177\/17474930221150349","journal-title":"Int J Stroke"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key437","article-title":"Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study","volume":"58","author":"Grimaud F","year":"2019","unstructured":"Grimaud F, Yelnik C, Pineton de Chambrun M, et al.. Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study. Rheumatology (Oxford). 2019, 58:1006-10. 10.1093\/rheumatology\/key437","journal-title":"Rheumatology (Oxford)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02971","article-title":"Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria","volume":"9","author":"Litvinova E","year":"2018","unstructured":"Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon-Durey MA. Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol. 2018, 9:2971. 10.3389\/fimmu.2018.02971","journal-title":"Front Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1696687","article-title":"Prevalence of antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: a long-term follow-up multicentre study","volume":"119","author":"Radin M","year":"2019","unstructured":"Radin M, Schreiber K, Sciascia S, Roccatello D, Cecchi I, Aguirre Zamorano M\u00c1, Cuadrado MJ. Prevalence of antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: a long-term follow-up multicentre study. Thromb Haemost. 2019, 119:1920-6. 10.1055\/s-0039-1696687","journal-title":"Thromb Haemost"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/389601","article-title":"The mosaic of \"seronegative\" antiphospholipid syndrome","volume":"2014","author":"Conti F","year":"2014","unstructured":"Conti F, Capozzi A, Truglia S, et al.. The mosaic of \"seronegative\" antiphospholipid syndrome. J Immunol Res. 2014, 2014:389601. 10.1155\/2014\/389601","journal-title":"J Immunol Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/321846-clinical-and-immunologic-manifestations-of-antiphospholipid-syndrome-among-patients-in-king-abdulaziz-medical-city-kamc-jeddah-saudi-arabia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T10:28:37Z","timestamp":1735727317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/321846-clinical-and-immunologic-manifestations-of-antiphospholipid-syndrome-among-patients-in-king-abdulaziz-medical-city-kamc-jeddah-saudi-arabia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.76720","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}